BioTuesdays

Tag - William Blair

Markets

WB starts Phreesia at OP

William Blair launched coverage of Phreesia (NYSE:PHR) with an “outperform” rating. The stock closed at $27.37 on Aug. 9. Phreesia, which went public in July 2019, gives healthcare organizations a suite of robust...

August 12, 2019
Markets

WB starts Addus HomeCare at OP

William Blair initiated coverage of Addus HomeCare (NASDAQ:ADUS) with an “outperform” rating, saying the company is one of the few ways for public market investors to play the in-home healthcare delivery theme, with a...

August 9, 2019
Markets

WB starts Actinium Pharma at OP

William Blair launched coverage of Actinium Pharmaceuticals (NASDAQ:ATNM) with an “outperform” rating based on its view that the company’s potent and specific radiopharmaceuticals for improving treatment options of...

August 8, 2019
AxoGen
Markets

WB cuts AxoGen to MP from OP

William Blair downgraded AxoGen (NASDAQ:AXGN) to “market perform” from “outperform” after the company reduced revenue guidance for 2019. The stock closed at $17.58 on Aug. 6, near the low end of its 52-week range of $14...

August 7, 2019
Markets

WB starts Change Healthcare at OP

William Blair launched coverage of Change Healthcare (NASDAQ:CHNG) with an “outperform” rating. The stock closed at $13.50 on July 19. Change Healthcare is a leading healthcare technology platform provider, offering...

July 22, 2019
Feature

William Blair analyst discusses Hep B space

By Len Zehr As a partner and biotechnology analyst with William Blair & Co., Y. Katherine Xu was recognized in 2010 by the Financial Times/StarMine “World’s Top Analysts” listing, ranking No. 7 overall for stock...

October 11, 2016